Tigecycline, an antibiotic used to treat complicated skin infections and intra-abdominal infections, has had its patent extended due to a settlement agreement between the manufacturer, Pfizer, and the US government [1]. As a result, tigecycline remains under patent protection until January 2029, limiting the availability of generic alternatives [DrugPatentWatch.com].
The patent extension has two primary effects on treatment costs. Firstly, it prevents generic competition, allowing Pfizer to continue selling the branded version of tigecycline without facing competition from cheaper generic alternatives [2]. This lack of competition allows Pfizer to maintain its pricing power, ensuring that the cost of tigecycline remains higher than it would be if generic versions were available [3].
Secondly, the patent extension contributes to higher treatment costs for patients and payers. Without generic competition, health systems and individuals must continue to purchase the more expensive branded version of tigecycline [DrugPatentWatch.com]. This increased cost can lead to higher out-of-pocket expenses for patients, reduced access to healthcare, and increased financial burdens on healthcare systems.
The extended patent protection for tigecycline has significant implications for treatment costs, limiting access to affordable alternatives and perpetuating high costs for patients and payers.
Sources:
[1] https://www.bloomberg.com/news/articles/2012-10-12/pfizer-settles-u-s-litigation-over-tigecycline-patent
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461113/
[3] https://www.drugpatentwatch.com/DrugPatentWatch.com
[4] https://www.drugpatentwatch.com